Latest Neurofibrillary tangle Stories
- Two Target Tau; Two May Reduce Tau Though Their Target Was Amyloid - HONOLULU, July 13 /PRNewswire-USNewswire/ -- The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques.
TGen-led team finds 3 proteins that dismantle 'bridges' within brain cells.
Protein reduces levels of amyloid beta and tau hyperphosphorylation, 2 hallmarks of Alzheimer's.
A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD).
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins â€“ beta amyloid and phosphorylated tau â€“ that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
VIENNA, July 15 /PRNewswire-USNewswire/ -- New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
New research has shown that a rogue protein thought to cause Alzheimer's can spread through the brain, turning healthy tissue bad.
Rare genetic disorder may benefit from development of new dementia treatments.
Scientists at UC Santa Barbara have discovered that a protein called BAG2 is important for understanding Alzheimer's disease and may open up new targets for drug discovery.
ProteoTech has completed regulatory investigational new drug requirements and has received clearance from the FDA to initiate its Phase I human clinical trial on Exebryl-1, a small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease.
- The governor of a province or people.